Crossmark

The MARIPOSA trials — implications for the treatment of EGFR-mutant NSCLC

Published Online: 2024-08-19

Published Print: 2024-11

Authors

Ardeshir-Larijani, Fatemeh

Ramalingam, Suresh S. http://orcid.org/0000-0002-0757-3106
License Information

Text and Data Mining valid from 2024-08-19

Version of Record valid from 2024-08-19
More Information

Article History

First Online: 19 August 2024

Competing interests

: S.S.R. has received institutional research grants for clinical trials support from Amgen, AstraZeneca, Bristol Myers Squibb, Merck and Pfizer. F.A.-L. declares no competing interests.

Document is current